Hydrocortisone acetate
Phase 2Small molecule
Hydrocortisone acetate is one of 26 small molecule programs targeting Hemorrhoid. It is currently in Phase 2.
1
Indications
5
Total Trials
0
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
72 competitors in Hemorrhoid
#DrugCompanyPhaseTrials
1Marcaine
IInnocoll
Approved
EXPAREL
Pacira Pharmaceuticals, IncApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Flagyl
DDePuy Orthopaedics
Phase 3
SKY0402
Pacira Pharmaceuticals, IncPhase 3
Botox
RRevance Therapeutics, Inc.
Phase 2
Centella
UUniversity of Roma La Sapienza
Approved
Xylocaine
CCitius Pharmaceuticals, Inc.
Phase 2
Morphine Chloride
FFundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias
Approved
Sebacoyl Dinalbuphine Ester
LLumosa Therapeutics Co., Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Depression2 trials
Hemorrhoid2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Hydrocortisone acetate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- NNivagen Pharmaceuticals Inc.